Medical device company CooperCompanies (NASDAQ:COO) will be reporting results tomorrow after market close. Here’s what you need to know.
CooperCompanies missed analysts’ revenue expectations by 0.8% last quarter, reporting revenues of $1.02 billion, up 9.8% year on year. It was a softer quarter for the company, with a miss of analysts’ full-year EPS guidance estimates.
Is CooperCompanies a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting CooperCompanies’s revenue to grow 5.2% year on year to $980.4 million, slowing from the 8.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.91 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CooperCompanies has missed Wall Street’s revenue estimates five times over the last two years.
Looking at CooperCompanies’s peers in the medical devices & supplies - diversified segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.4%, beating analysts’ expectations by 3.3%, and Baxter reported flat revenue, topping estimates by 3.4%. Boston Scientific traded up 1.5% following the results while Baxter was also up 9.8%.
Read our full analysis of Boston Scientific’s results here and Baxter’s results here.
Stocks, especially growth stocks where cash flows further in the future are more important to the story, had a good 2024. An economic soft landing (so far), the start of the Fed's rate cutting campaign, and the election of Donald Trump were positives for the market, and while some of the medical devices & supplies - diversified stocks have shown solid performance, the group has generally underperformed, with share prices down 7.3% on average over the last month. CooperCompanies is down 5% during the same time and is heading into earnings with an average analyst price target of $111.47 (compared to the current share price of $90.67).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.